Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN®-Filo and Ad26.ZEBOV administered in different sequences at Days 1 and 29 in healthy adult subjects aged 18 - 45 years.The study will evaluate the 'omics (transcriptomics, proteomics, lipidomics, metabolomics), antibodies for immunogenicity, CMI, ADCC, lymphoproliferative and plasmablast responses to MVA-BN®-Filo and Ad26.ZEBOV vaccines. The primary objectives of this study are: 1) To Assess the safety and reactogenicity of each study group. 2) To assess responses to the study vaccination by study group after the first, second and third dose by transcriptomics. 3) To assess the peak antibody response to the study vaccination by study group to filovirus antigens.


Clinical Trial Description

This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN®-Filo and Ad26.ZEBOV administered in different sequences at Days 1 and 29 in healthy adult subjects aged 18 - 45 years. The two heterologous prime-boost groups will also receive MVA-BN®-Filo at day 366. Sixty subjects will be randomized 1:1:1:1 to one of four study groups (15 per group).Subjects and study staff will be blinded to a subject's study vaccine assignment within study vaccination schedule (e.g., enrollment into Group 1 or 4 versus 2 or 3 will be known). The study will evaluate the 'omics (transcriptomics, proteomics, lipidomics, metabolomics), antibodies for immunogenicity, CMI, ADCC, lymphoproliferative and plasmablast responses to MVA-BN®-Filo and Ad26.ZEBOV vaccines. The primary objectives of this study are: 1) To Assess the safety and reactogenicity of each study group. 2) To assess responses to the study vaccination by study group after the first, second and third dose by transcriptomics. 3) To assess the peak antibody response to the study vaccination by study group to filovirus antigens. Secondary objectives are: 1) To assess antigen-specific cell-mediated immune (CMI) responses to the study vaccination by study group.2) To Assess antibody-dependent cell-mediated cytotoxicity (ADCC) responses to the study vaccination by study group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02891980
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Active, not recruiting
Phase Phase 1
Start date March 24, 2017
Completion date March 15, 2019

See also
  Status Clinical Trial Phase
Completed NCT02575456 - A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine Phase 2